Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 7/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468873 | 0.93 | MAPT (0.81) | POLBMAPTTHRBUSP2TP53 | |
| SCHEMBL11356053 | 0.92 | MAPT (0.84) | POLBMAPTTHRBTDP1USP2 | |
| SCHEMBL15324597 | 0.91 | MAPT (0.71) | POLBMAPTTHRBUSP2TP53 | |
| SCHEMBL12469777 | 0.91 | MAPT (0.71) | POLBMAPTTHRBUSP2MEN1 | |
| SCHEMBL12469495 | 0.91 | MAPT (0.70) | POLBMAPTTHRBUSP2HTT | |
| SCHEMBL27938291 | 0.91 | MAPT (0.70) | POLBMAPTTHRBUSP2TP53 | |
| SCHEMBL15325971 | 0.90 | MAPT (0.69) | POLBMAPTTHRBUSP2TP53 | |
| SCHEMBL12468976 | 0.90 | MAPT (0.69) | POLBMAPTTHRBUSP2HTT | |
| SCHEMBL12469088 | 0.90 | MAPT (0.69) | POLBMAPTTHRBUSP2MEN1 | |
| SCHEMBL15430795 | 0.89 | MAPT (0.68) | POLBMAPTTHRBUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | claimed |
| US-9079859-B2 | Synthetic lethal targeting of glucose transport | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-14 | — | — | US | claimed |
| EP-2838534-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2015-02-25 | — | — | EP | claimed |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | RUGA CORPORATION | 2014-05-08 | — | — | US | claimed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | claimed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | claimed |
| EP-2627324-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051117-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-19 | — | — | WO | claimed |
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | disclosed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | disclosed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2012100223-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | IRWIN JOHN (US) | 2012-07-26 | — | — | WO | disclosed |
| EP-0000125-B1 | TENSIO-ACTIVE ESTERS OF PHOSPHORIC ACID AND THEIR UTILISATION | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | POLB 970/4885MAPT 2582/4885THRB 2141/4885 |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | NISCH, BTD, NAAA | POLB 970/4885MAPT 2582/4885THRB 2141/4885 |
| US-20140128397-A1 | SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT | SLC2A1, SLC2A3, SLC2A2 | POLB 1890/4885MAPT 4397/4885THRB 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.